Hormonal profile, the PROGINS polymorphism, and erectile dysfunction complaints: data from a population-based survey.
Andersen ML, Alvarenga TA, Mazzotti DR, Guindalini C, Pellegrino R, Barrueco KF, Santos-Silva R, Bittencourt LR, Tufik S
Departamento de Psicobiologia-Universidade Federal de São Paulo, Sao Paulo, Brazil. mandersen@psicobio.epm.br
Published 24 January 2011 in Fertil Steril, 95(2): 621-4.
Full-text of this article is available online (may require subscription).
Articles on Impotence published 13 January 2011:
Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol, 185(2): 614-8.
[Abstract] [Full-text]
Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: up to 7.7 years of followup. J Urol, 185(2): 614-8.
[Abstract] [Full-text]
Articles on Impotence published 3 January 2011:
Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction. Urology, 77(1): 119-22.
[Abstract] [Full-text]
Articles on Impotence published 20 December 2010:
Where cost, medical necessity, and morality meet: should US government insurance programs pay for erectile dysfunction drugs? Clin Pharmacol Ther, 89(1): 17-9.
Spending for the three most popular phosphodiesterase (PDE) inhibitor drugs to treat erectile dysfunction (ED) tops $1 billion worldwide annually. Using Medicaid and Medicare Part D as examples, we explore here whether US government insurance programs with limited budgets should reimburse for this class of ED drugs and review the common bases for justifying and denying reimbursement. We conclude that the clinical usefulness and costs of such drugs should be the primary drivers of coverage ... [Abstract] [Full-text]
Where cost, medical necessity, and morality meet: should US government insurance programs pay for erectile dysfunction drugs? Clin Pharmacol Ther, 89(1): 17-9.
Spending for the three most popular phosphodiesterase (PDE) inhibitor drugs to treat erectile dysfunction (ED) tops $1 billion worldwide annually. Using Medicaid and Medicare Part D as examples, we explore here whether US government insurance programs with limited budgets should reimburse for this class of ED drugs and review the common bases for justifying and denying reimbursement. We conclude that the clinical usefulness and costs of such drugs should be the primary drivers of coverage ... [Abstract] [Full-text]
Articles on Impotence published 14 December 2010:
Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial. J Urol, 185(1): 243-8.
[Abstract] [Full-text]
Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial. J Urol, 185(1): 243-8.
[Abstract] [Full-text]
Articles on Impotence published 24 November 2010:
Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 78(5): 1292-300.
[Abstract] [Full-text]
© 2004-2011 Impotence Research Today. All Rights Reserved.
| 
